A Randomized, Multicenter, Phase III Open-label Study of the Efficacy and Safety of Trastuzumab MCC-DM1 vs. Capecitabine + Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-Based Therapy

Trial Profile

A Randomized, Multicenter, Phase III Open-label Study of the Efficacy and Safety of Trastuzumab MCC-DM1 vs. Capecitabine + Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-Based Therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Trastuzumab emtansine (Primary) ; Capecitabine; Lapatinib
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms EMILIA
  • Sponsors Roche
  • Most Recent Events

    • 10 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 07 Jun 2016 Results of substudy presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 26 Feb 2016 Results of exploratory biomarker analysis published in the Clinical cancer research: an official journal of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top